1636. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation

BACKGROUND: The risk of latent tuberculosis infection (LTBI) reactivation in cancer patients during checkpoint inhibitor immunotherapy (CPI) remains largely unknown. We sought to evaluate LTBI therapy and outcomes between cancer patients receiving CPI versus conventional chemotherapy (CC) and hemato...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Malek, Alexandre, Chaftari, Patrick, dagher, Hiba, Hachem, Ray Y, Chaftari, Anne-Marie, Viola, George, Raad, Issam I
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Poster Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777861/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1816
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky